Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Allopurinol and Febuxostat in APRT Deficiency
NCT02752633Phase 4Completed
- Sponsor
- Landspitali
- Start
- May 2013
- Primary completion
- May 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of febuxostat in adenine phosphoribosyltransferase deficiency (APRT-D), sponsored by Landspitali. Primary endpoint: Urinary 2,8-dihydroxyadenine Excretion at 42 days. Started May 2013; status: completed.
02
Drugs
febuxostat
03
Conditions
adenine phosphoribosyltransferase deficiency (APRT-D)
Beyond the preview
Go deeper on NCT02752633.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02752633.